原发性胆汁性胆管炎的诊断与管理指南（2021年）
Guidelines on the Diagnosis and Management of Primary Biliary Cholangitis (2021).
作者信息
You Hong, Duan Weijia, Li Shuxiang, Lv Tingting, Chen Sha, Lu Lungen, Ma Xiong, Han Ying, Nan Yuemin, Xu Xiaoyuan, Duan Zhongping, Wei Lai, Jia Jidong, Zhuang Hui
机构信息
Liver Research Center, Beijing Friendship Hospital, Capital Medical University & National Clinical Research Center for Digestive Diseases, Beijing, China.
Department of Gastroenterology, First People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
出版信息
J Clin Transl Hepatol. 2023 Jun 28;11(3):736-746. doi: 10.14218/JCTH.2022.00347. Epub 2023 Feb 10.
Abstract
In 2015, the Chinese Society of Hepatology and the Chinese Society of Gastroenterology published a consensus on primary biliary cholangitis (PBC). In the past years, numerous clinical studies have been published in the field of PBC. To guide the clinical diagnosis and management of PBC patients, the Chinese Society of Hepatology invited a panel of experts to assess the new clinical evidence and formulate the current guidelines.
摘要
2015年，中华医学会肝病学分会和中华医学会消化病学分会发表了原发性胆汁性胆管炎（PBC）的共识。在过去几年中，PBC领域发表了大量临床研究。为指导PBC患者的临床诊断和管理，中华医学会肝病学分会邀请了一组专家评估新的临床证据并制定了本版指南。
相似文献
1
Guidelines on the Diagnosis and Management of Primary Biliary Cholangitis (2021).原发性胆汁性胆管炎的诊断与管理指南（2021年）
J Clin Transl Hepatol. 2023 Jun 28;11(3):736-746. doi: 10.14218/JCTH.2022.00347. Epub 2023 Feb 10.
2
[Guidelines on the diagnosis and management of primary biliary cholangitis (2021)].[原发性胆汁性胆管炎的诊断和管理指南（2021年）]
Zhonghua Gan Zang Bing Za Zhi. 2022 Mar 20;30(3):264-275. doi: 10.3760/cma.j.cn112138-20211112-00794-1.
3
[Guidelines on the diagnosis and management of primary biliary cholangitis (2021)].[原发性胆汁性胆管炎的诊断和管理指南（2021年）]
Zhonghua Nei Ke Za Zhi. 2021 Dec 1;60(12):1024-1037. doi: 10.3760/cma.j.cn112138-20211112-00794.
4
Diagnosis and Management of Primary Biliary Cholangitis.原发性胆汁性胆管炎的诊断与治疗。
Am J Gastroenterol. 2019 Jan;114(1):48-63. doi: 10.1038/s41395-018-0390-3.
5
The National Audit of Primary Biliary Cholangitis (PBC) in the United Kingdom: Defining the Audit Dataset and Data Collection System.英国原发性胆汁性胆管炎（PBC）国家审计：定义审计数据集和数据收集系统。
Cureus. 2022 Jun 2;14(6):e25609. doi: 10.7759/cureus.25609. eCollection 2022 Jun.
6
Setting Up a Local Registry to Improve the Care of Patients With Primary Biliary Cholangitis.建立本地登记系统以改善原发性胆汁性胆管炎患者的护理。
Cureus. 2022 May 23;14(5):e25247. doi: 10.7759/cureus.25247. eCollection 2022 May.
7
The impact of undiagnosed primary biliary cholangitis.原发性胆汁性胆管炎未确诊的影响。
Eur J Gastroenterol Hepatol. 2021 Dec 1;33(1S Suppl 1):e1027-e1031. doi: 10.1097/MEG.0000000000002268.
8
[An interpretation of 2017 EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis].《2017 欧洲肝脏研究学会临床实践指南解读：原发性胆汁性胆管炎患者的诊断与管理》
Zhonghua Gan Zang Bing Za Zhi. 2017 Nov 20;25(11):814-818. doi: 10.3760/cma.j.issn.1007-3418.2017.11.004.
9
UPDATE OF THE BRAZILIAN SOCIETY OF HEPATOLOGY RECOMMENDATIONS FOR DIAGNOSIS AND MANAGEMENT OF AUTOIMMUNE DISEASES OF THE LIVER.巴西肝病学会关于自身免疫性肝病诊断与管理的推荐更新
Arq Gastroenterol. 2019 Aug 13;56(2):232-241. doi: 10.1590/S0004-2803.201900000-43.
10
[Guidelines on the diagnosis and management of primary sclerosing cholangitis (2021)].[原发性硬化性胆管炎的诊断与管理指南（2021年）]
Zhonghua Gan Zang Bing Za Zhi. 2022 Feb 20;30(2):169-189. doi: 10.3760/cma.j.cn112138-20211109-00786.
引用本文的文献
1
Liver immunology: Biological role and clinical significance.肝脏免疫学：生物学作用及临床意义。
World J Hepatol. 2025 Jul 27;17(7):107541. doi: 10.4254/wjh.v17.i7.107541.
2
A Case of Hepatic Encephalopathy With Diffuse Brainstem Signal Changes on Magnetic Resonance Imaging.一例磁共振成像显示弥漫性脑干信号改变的肝性脑病病例。
Cureus. 2025 Mar 26;17(3):e81217. doi: 10.7759/cureus.81217. eCollection 2025 Mar.
3
Patients with AMA/anti-sp100/anti-gp210 Positivity and Cholestasis Can Manifest Conditions Beyond Primary Biliary Cholangitis.AMA/抗sp100/抗gp210阳性且伴有胆汁淤积的患者可能表现出原发性胆汁性胆管炎以外的病症。
J Clin Transl Hepatol. 2025 Mar 28;13(3):200-206. doi: 10.14218/JCTH.2024.00374. Epub 2025 Jan 17.
4
Correspondence to editorial on "Prediction of primary biliary cholangitis among health check-up population with anti-mitochondrial M2 antibody positive".致关于“抗线粒体M2抗体阳性健康体检人群中原发性胆汁性胆管炎的预测”的社论的信函
Clin Mol Hepatol. 2025 Apr;31(2):e194-e196. doi: 10.3350/cmh.2025.0181. Epub 2025 Feb 24.
5
Analysis of C4 Concentrations to Predict Impact of Patient-Reported Diarrhea Associated With the Ileal Bile Acid Transporter Inhibitor Linerixibat.分析C4浓度以预测与回肠胆汁酸转运体抑制剂利奈昔布相关的患者报告腹泻的影响。
CPT Pharmacometrics Syst Pharmacol. 2025 Mar;14(3):596-605. doi: 10.1002/psp4.13300. Epub 2025 Feb 13.
6
Current Treatment Regimens and Promising Molecular Therapies for Chronic Hepatobiliary Diseases.慢性肝胆疾病的当前治疗方案及有前景的分子疗法
Biomolecules. 2025 Jan 14;15(1):121. doi: 10.3390/biom15010121.
7
An atypical presentation of autoimmune hepatitis with delayed menarche in a Nigerian adolescent: a case report.一名尼日利亚青少年自身免疫性肝炎伴初潮延迟的非典型表现：病例报告
J Med Case Rep. 2025 Jan 24;19(1):34. doi: 10.1186/s13256-025-05051-2.
8
Biliary fibrosis is an important but neglected pathological feature in hepatobiliary disorders: from molecular mechanisms to clinical implications.胆汁纤维化是肝胆疾病中一个重要但被忽视的病理特征：从分子机制到临床意义。
Med Rev (2021). 2024 Jul 1;4(4):326-365. doi: 10.1515/mr-2024-0029. eCollection 2024 Aug.
9
Elafibranor: First Approval.依洛尤单抗：美国批准上市
Drugs. 2024 Sep;84(9):1143-1148. doi: 10.1007/s40265-024-02075-8. Epub 2024 Aug 7.
10
Case report: Rare benign obstructive disease of the biliary tract-a rare case of eosinophilic cholangitis.病例报告：罕见的良性胆道阻塞性疾病——嗜酸性胆管炎一例罕见病例。
Front Med (Lausanne). 2024 Jan 17;10:1340667. doi: 10.3389/fmed.2023.1340667. eCollection 2023.
本文引用的文献
1
The future risk of primary biliary cholangitis (PBC) is low among patients with incidental anti-mitochondrial antibodies but without baseline PBC.在无基线原发性胆汁性胆管炎（PBC）但存在偶然抗线粒体抗体的患者中，原发性胆汁性胆管炎（PBC）的未来风险较低。
Hepatol Commun. 2022 Nov;6(11):3112-3119. doi: 10.1002/hep4.2067. Epub 2022 Aug 23.
2
Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis.振动控制瞬时弹性成像测量肝硬度可改善原发性胆汁性胆管炎的预后预测。
J Hepatol. 2022 Dec;77(6):1545-1553. doi: 10.1016/j.jhep.2022.06.017. Epub 2022 Jun 28.
3
Concomitant extrahepatic autoimmune diseases do not compromise the long-term outcomes of primary biliary cholangitis.合并肝外自身免疫性疾病并不影响原发性胆汁性胆管炎的长期预后。
Hepatobiliary Pancreat Dis Int. 2022 Dec;21(6):577-582. doi: 10.1016/j.hbpd.2022.05.009. Epub 2022 May 24.
4
APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis.亚太肝脏研究学会临床实践指南：原发性胆汁性胆管炎患者的诊断与管理
Hepatol Int. 2022 Feb;16(1):1-23. doi: 10.1007/s12072-021-10276-6. Epub 2022 Feb 4.
5
Environmental factors, medical and family history, and comorbidities associated with primary biliary cholangitis in Japan: a multicenter case-control study.日本原发性胆汁性胆管炎的环境因素、医疗和家族史及合并症：一项多中心病例对照研究。
J Gastroenterol. 2022 Jan;57(1):19-29. doi: 10.1007/s00535-021-01836-6. Epub 2021 Nov 18.
6
Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases.原发性胆汁性胆管炎：美国肝病研究协会2021年实践指南更新
Hepatology. 2022 Apr;75(4):1012-1013. doi: 10.1002/hep.32117. Epub 2021 Dec 20.
7
Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis.奥贝胆酸暴露对原发性胆汁性胆管炎和肝硬化失代偿及死亡率的影响。
Hepatol Commun. 2021 May 6;5(8):1426-1436. doi: 10.1002/hep4.1720. eCollection 2021 Aug.
8
Management of Sjögren's Syndrome: Present Issues and Future Perspectives.干燥综合征的管理：当前问题与未来展望
Front Med (Lausanne). 2021 Jun 7;8:676885. doi: 10.3389/fmed.2021.676885. eCollection 2021.
9
Fenofibrate improves GLOBE and UK-PBC scores and histological features in primary biliary cholangitis.非诺贝特可改善原发性胆汁性胆管炎的GLOBE和UK-PBC评分以及组织学特征。
Minerva Med. 2022 Dec;113(6):974-982. doi: 10.23736/S0026-4806.21.07316-X. Epub 2021 May 5.
10
Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis.熊去氧胆酸治疗妊娠肝内胆汁淤积症：系统评价和个体参与者数据荟萃分析。
Lancet Gastroenterol Hepatol. 2021 Jul;6(7):547-558. doi: 10.1016/S2468-1253(21)00074-1. Epub 2021 Apr 27.
Zotero 插件